Pharmafile Logo

CAR-Ts

- PMLiVE

Novartis and Precision BioSciences announce in vivo gene editing collaboration

The companies will work together to develop potentially curative treatments for disorders including sickle cell disease and beta thalassaemia

- PMLiVE

Lilly links up with Precision BioSciences in genome editing deal

Precision will receive an upfront cash payment of $100m

- PMLiVE

Precision BioSciences to raise $100m for off the shelf CAR-Ts

Joins next wave of cell therapy competitors

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

Gilead strikes deal with NHS England on CAR-T Yescarta

NHS England claims adult leukaemia access is first in Europe

- PMLiVE

Kymriah rejected in DLBCL – but NICE wants to keep talking about cost effectiveness

Kymriah faces harder test in DLBCL - especially with Yescarta competition

- PMLiVE

London cancer hub launched by Cancer Research UK

Specialist centres unite to collaborate on immunotherapies such as CAR-T

Gilead Sciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Biopharma looks to genome editing platform to discover hepatitis B cure

- PMLiVE

Novartis and Gilead rival CAR-Ts approved in Europe, but supply capacity in question

Gilead looks to have edge in crucial manufacturing capability

- PMLiVE

It’s a no for Yescarta, says NICE on heels of EU approval

Gilead gets rapid knock-back from cost effectiveness watchdog

- PMLiVE

CAR-Ts Kymriah and Yescarta step closer to approval in Europe

Final European approval around the corner - but reimbursement and specialist centres among outstanding issues

- PMLiVE

New trial results suggest CAR-T effects are durable in lymphoma

Novartis and Celgene/Juno release longer term data on important lymphoma indication at EHA

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links